People buy more soda when offered packs of smaller sizes than if buying single large drink
Restricting soda servings may induce people to buy more soda than when offered larger sized drinks
People buy larger amounts of soda when purchasing packs of smaller drinks than when offered single servings of different sized drinks, according to research published April 10 in the open access journal PLOS ONE by Brent M. Wilson and colleagues from the University of California, San Diego.
The researchers tested the effects of limiting sugary drink sizes on people’s soda consumption by offering them three kinds of menus. One menu offered 16 , 24 or 32 ounce sized individual drinks, a second gave them the choices of a 16 oz. drink, or bundles of two 12 ounce drinks or two 16 ounce drinks, and a third menu offered only individual 16 oz. drinks for sale. When participants made choices from these menus as they would in a fast food restaurant, people bought more soda from the menu with packs of 12 oz. or 16 oz. drinks than they did when offered individual sodas of different sizes. Based on the choices participants made, total business revenues were also higher when menus included packs of drinks rather than only small sized drinks.
The study concludes that when drink sizes are limited, businesses may have a strong incentive to offer packs of several small drinks rather than only individual servings. The authors suggest that restricting larger servings of sugary drinks in efforts to moderate may thus have the unintended outcome of increasing soda consumption rather than reducing it.
“Our research shows the New York City ban on large-sized drinks may have unintended consequences that policy makers need to consider. Sugary drinks are a major source of business revenue, and businesses will adjust their menus in order to maximize profits,” says Wilson.
Citation: Wilson BM, Stolarz-Fantino S, Fantino E (2013) Regulating the Way to Obesity: Unintended Consequences of Limiting Sugary Drink Sizes. PLOS ONE 8(4): e61081. doi:10.1371/journal.pone.0061081
Financial Disclosure: These authors have no support or funding to report.
Competing Interest Statement: The authors have declared that no competing interests exist.
PLEASE LINK TO THE SCIENTIFIC ARTICLE IN ONLINE VERSIONS OF YOUR REPORT (URL goes live after the embargo ends): http://dx.plos.org/10.1371/journal.pone.0061081
Disclaimer: This press release refers to upcoming articles in PLOS ONE. The releases have been provided by the article authors and/or journal staff. Any opinions expressed in these are the personal views of the contributors, and do not necessarily represent the views or policies of PLOS. PLOS expressly disclaims any and all warranties and liability in connection with the information found in the release and article and your use of such information.
About PLOS ONE: PLOS ONE is the first journal of primary research from all areas of science to employ a combination of peer review and post-publication rating and commenting, to maximize the impact of every report it publishes. PLOS ONE is published by the Public Library of Science (PLOS), the open-access publisher whose goal is to make the world’s scientific and medical literature a public resource.
All works published in PLOS ONE are Open Access. Everything is immediately available—to read, download, redistribute, include in databases and otherwise use—without cost to anyone, anywhere, subject only to the condition that the original authors and source are properly attributed. For more information about PLOS ONE relevant to journalists, bloggers and press officers, including details of our press release process and our embargo policy, see the everyONE blog at http://everyone.plos.org/media.
Categories: Health Technology News